Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Medical
- Supply
- Stent
- Coating
- Chemicals
- Surgical
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 7540
License Grant
The amendment addresses regulatory responsibility for the original agreement where Licensor grants to the Israeli Licensee a non-exclusive, worldwide license for production and use of the MGuard Prime cobalt-chromium stent for the life of the stent’s patent.
License Property
The current MGuard Prime version of our MGuard Coronary with a bio-stable mesh is comprised of our mesh sleeve wrapped around a cobalt-chromium bare-metal stent. In comparison to a conventional bare-metal stent, we believe the MGuard Coronary with a bio-stable mesh provides protection from embolic showers.
IPSCIO Record ID: 7539
License Grant
Licensor grants us a non-exclusive, worldwide license for production and use of the MGuard Prime cobalt-chromium stent for the life of the stent’s patent.
License Property
The current MGuard Prime version of our MGuard Coronary with a bio-stable mesh is comprised of our mesh sleeve wrapped around a cobalt-chromium bare-metal stent. In comparison to a conventional bare-metal stent, we believe the MGuard Coronary with a bio-stable mesh provides protection from embolic showers.
IPSCIO Record ID: 209508
License Grant
Licensor, of the Netherlands, grants a non-exclusive, worldwide license to import, export, use, sell, and offer for sale Licensees Stents utilizing, incorporating or coated with Licensors Drug/Polymer Composite Formulation, Biolimus A9 and/or Licensors Polymer Coating in Licensees Licensed Field of Use; and
At Licensees option, a non-exclusive, worldwide license to import, export, use, sell, and offer for sale Licensee Stent Systems incorporating or utilizing Licensors Lubricious Coating.
License Property
The Coated Stents means Licensees Stents marketed, developed or sold by Licensee and coated with Licensors Polymer Coating, Occams Drug/Polymer Composite Formulation, or Biolimus A9.
The Covered Products means either or both Coated Stents and Licensee Stent Systems incorporating or utilizing Licensors Lubricious Coating.
The patents relate to Endovascular Stents and coatings.
Biolimus A9 is formulated to inhibit excessive tissue formation around the stent following implantation, a common side effect called restenosis which often threatens to reverse the clinical benefits of the angioplasty and stent implantation procedures.
Field of Use
Licensees Licensed Field of Use means any applications, procedures, processes or other uses related to drug-eluting, commonly delivered Stents that are delivered as a series of short stents on a delivery catheter wherein the operator has the ability to select the number of short stents as a portion of the total number of stents in the series to be deployed, solely for use in coronary and peripheral vascular applications.
In Japan, Licensees Licensed Field of Use is further limited to treating long lesions, multiple vessels or small vessels in coronary and peripheral applications.
IPSCIO Record ID: 26181
License Grant
The recent European marketing approval for the latest drug-coated stent technology, which prevents blocked arteries, highlighted a licensing transaction from early 2006 between two U.S. pharmaceutical companies.
License Property
The Promus Element stent will be marketed in the European Union immediately. The device replaces the older Promus stent, which is the licensee's version of the Xience stent.
Field of Use
The field of use relates to the medical industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
